Mobile

A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastat...

Update Il y a 4 ans
Reference: EUCTR2005-002570-30

A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Neuroprotection: Reduction in the risk of occurrence of Grade 3-4 cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin.

Inclusion criteria

  • Patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV at risk of cumulative peripheral sensory neuropathy PSN relative to cumulative dose of oxaliplatin

Links